MG
CATX icon

Michael Gelband’s Perspective Therapeutics CATX Stock Holding History

Michael Gelband’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-117,051
Closed -$488K – 1616
2026
Q1 		$488K Buy
+117,051
New +$495K ﹤0.01% 1198
2024
Q4 		– Sell
-581,614
Closed -$7.76M – 1567
2024
Q3 		$7.76M Sell
581,614
-14,440
-2% -$192K 0.05% 283
2024
Q2 		$5.94M Buy
596,054
+307,160
+106% +$4.44M 0.04% 358
2024
Q1 		$3.44M Buy
+288,894
New +$2.46M 0.03% 515
2023
Q2 		– Sell
-4,872
Closed -$31K – 1878
2023
Q1 		$31K Buy
+4,872
New +$19.9K ﹤0.01% 1679

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Michael Gelband's CATX Position: Q2 2026 in Review

Michael Gelband sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 117,051 shares — an estimated $488K sold.

Michael Gelband first reported a position in CATX in Q1 2023 and held it in 5 quarters. The position peaked at $7.76M in Q3 2024. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Michael Gelband reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 117,051 Perspective Therapeutics shares in Q2 2026, an estimated $488K.
  • Michael Gelband first reported a position in Perspective Therapeutics in Q1 2023 and held it in 5 quarters.
  • Michael Gelband's Perspective Therapeutics position peaked at $7.76M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.